Slide 1: Company Presentation
Company Presentation October 2026 AIM: POLB
Slide 2: Disclaimer
Disclaimer The contents of this presentation and the informati on which you are gi ven at the time of the presentation hav e not been approved by an aut horised person within the meaning of the Fi nancial Serv ices and Markets Act 2000 (the “Act”). Reliance on this presentation for the purpose of en
Slide 3: Company Overview
Company Overview Experienced team with proven track record of closing A clinical-stage company 1 significant transactions developing POLB 001 that has the potential to transform the lives of cancer patients by delivering their 2 High value clinical-stage programmes targeting critical unmet medical n
Slide 4: High Value Pipeline Programmes
High Value Pipeline Programmes Multiple near-term clinical value inflection points – positioned well for partnering Product Modality Indication Preclinical Phase 1 Phase 2 Phase 3 Key Milestones ▪ TOPICAL trial in multiple Cancer myeloma patients POLB 001 p38 MAPK Immunotherapy- FDA Orphan inhibitor
Slide 5: POLB 001 – potential first approved preventative therapy for cancer immunotherapy-induced CRS
POLB 001 – potential first approved preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome (CRS) POLB 001 has the potential to transform the cancer immunotherapy field through the prevention of CRS, thereby expanding administration of these life-saving therapies from central
Slide 6: POLB 001 as a Potential Solution For CRS
POLB 001 as a Potential Solution For CRS A systemic inflammatory side effect of some cancer immunotherapies Clinical Manifestations • POLB 001 is an oral p38 MAP Kinase inhibitor • p38 MAPK acts as a gatekeeper to inflammatory responses Heart Rate Fever • Inhibition causes a potent decrease of a wid
Slide 7: POLB 001: Executive Summary
POLB 001: Executive Summary Potential to make cancer immunotherapies safer and more accessible p38 MAPK INHIBITOR STRONG PRECLINICAL & CLINICAL DATA SIGNIFICANT MARKET OPPORTUNITY • Selectively prevents excessive • Favourable safety & tolerability • FDA agreed on Phase 3 endpoint & inflammation with
Slide 8: POLB 001's Intended Impact: An Illustrative Patient Journey
POLB 001's Intended Impact: An Illustrative Patient Journey Transforming cancer care for patients and healthcare systems Patient 1 Current Standard of Care Patient 2 Utilising POLB 001 Cancer immunotherapies redirect the Patient takes POLB 001 before 1 immune system to fight cancer 1 cancer immunoth
Slide 9: Phase 1b LPS Human Challenge – Potent Inhibition of Excessive Inflammation
Phase 1b LPS Human Challenge – Potent Inhibition of Excessive Inflammation ASH ‘23 Positive data supports the potential of POLB 001 to effectively prevent CRS Phase 1b LPS Human Challenge Trial IL-6 Levels IL-8 levels • Excellent safety & tolerability profile • Potent target inhibition confirmed • C
Slide 10: First-in-Patient TOPICAL Trial
POLB 001 First-in-Patient TOPICAL Trial J&J supplying the approved bispecific antibody teclistamab TOPICAL - Trial of Prevention of ImmunoCytokine Adverse events in Myeloma Leading Cancer Research Centres Chief Investigator Dr Emma Searle, MBChB MA MRCP FRCPath PhD 1. The Christie, Manchester 5 Tria
Slide 11: First-in-Patient TOPICAL Trial
POLB 001 First-in-Patient TOPICAL Trial Trial designed to produce rapid & compelling data for the effectiveness of POLB 001 to prevent CRS Trial Design Key Endpoints Tec Tec Weekly Weekly • Safety of POLB 001 Dose 1 Dose 2 Dosing Dosing • Incidence of CRS Day* -4 … 1 2 3 4 5 6 7 … 14 … High Risk Per
Slide 12: Trial is Designed to Generate Clinical Data Quickly
POLB 001 Trial is Designed to Generate Clinical Data Quickly Focused 1-2 month CRS monitoring window, versus multi-year outcomes monitoring in a typical oncology trial Short, focused trial design Short-term Monitoring 1-2 Months Timeline of a Trial Participant Typical oncology trials tend to take ye
Slide 13: Activities Completed to Reach Key Milestones
POLB 001 – Activities Completed to Reach Key Milestones Motivated study team & partners efficiently advancing TOPICAL trial All regulatory approvals Support site set up ✓ Motivated MDT✓ Protocol execution✓ received for TOPICAL trial ✓ POLB 001 Trial Site Initiation MHRA Regulatory Approval Patient I
Slide 14: TOPICAL Clinical Trial Interim Data
TOPICAL Clinical Trial Interim Data Completion of the review represents important milestone for POLB 001 clinical development Positive recommendation to continue the study as planned Interim Data Safety Review POLB 001 TOPICAL Trial Business Development Complete Recruitment continues Advancing Partn
Slide 15: Clear Route to Market
Clear Route to Market Programme positioned for rapid clinical development following TOPICAL study FDA pre-IND meeting conducted in May 2026 • Significant clarity achieved on nonclinical package, indication, Phase 3 design and Phase 3 endpoints • Feedback was aligned with: − The Company’s envisioned
Slide 16: Significant Market Opportunity in a Rapidly Growing Field
Significant Market Opportunity in a Rapidly Growing Field CRS is a major issue and rate limiting in delivering cancer immunotherapies CRS Rates for Approved Cancer Immunotherapies BsAb & CAR T Market Expected to Grow Exponentially Combined % Patients Drug Company with All-Grade CRS* $120bn Bispecifi
Slide 17: Prevention of CRS May Transform Cancer Immunotherapies
Prevention of CRS by POLB 001 May Transform Cancer Immunotherapies Potential to greatly enhance uptake and access to BsAb and CAR-T therapies by removing bottleneck From 2023 to 2030 Bottleneck* An effective CRS ~500,000 patients1 will be diagnosed preventative therapy may with DLBCL & MM in the US
Slide 18: US Payer and Pricing Insights
US Payer and Pricing Insights Payer willingness-to-pay research & economic arguments to support pricing readiness Independent Payer Research Covering ~75M Lives Across Insurance Providers, Medicare & Medicaid "This research validates both the scale of that unmet need and the appetite among payers fo
Slide 19: POLB 001 – Built for Partnering
POLB 001 – Built for Partnering Scientific, clinical, regulatory and commercial workstreams progressed in parallel to strengthen the partnering package Potential preventative therapy for cancer immunotherapy-induced CRS SCI ENTIFIC CLINICAL REGULATORY Scientific rationale Clinical execution Developm
Slide 20: Partnering Focussed
Partnering Focussed Effective preventative therapy represents a >US$10B market opportunity Pharma Seeking Assets Discussions Ongoing • Growing number of CRS-inducing cancer • Data room open and under review by multiple immunotherapies in the clinic parties • Pharma patent cliff - - ~US$400bn+ in rev
Slide 21: GLP-1 Programme
GLP-1 Programme Oral encapsulated GLP-1R agonist targeting the obesity market 21
Slide 22: GLP-1 Market Oral GLP-1
GLP-1 Market Oral GLP-1 A differentiated approach US$20.2 billion • Generally Recognised as Safe (GRAS) oral encapsulation 2025 marked a record year for technology encapsulates an approved GLP-1 receptor agonist obesity and diabetes deal-making • Directing GLP-1 receptor agonist to a specific area o
Slide 23: Proof of Concept Trial Planned to Commence H2 2026
Proof of Concept Trial Planned to Commence H2 2026 Successful results from the trial may support partnering & multiple opportunities for value creation Trial Investigator: Prof Carel le Roux Site: University of Ulster Objective: Demonstrate GLP-1 uptake The study has been designed to complete quickl
Slide 24: Summary
Summary 1 Experienced team with proven track record of closing significant transactions 2 High value clinical-stage programmes targeting critical unmet medical needs in large & growing markets 3 Partnering focused model with clear path to strategic transactions 4 Financial runway into Q2 2028 24
Slide 25: Stay in touch
Stay in touch Listed on the London Stock Exchange Ticker: POLB Register for RNS alerts 25
Slide 26: Appendix
POOLBEG PHARMA Appendix
Slide 27: Leadership Team with Record of Delivering Value
Leadership Team with Record of Delivering Value A clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field Cathal Friel Jeremy Skillington PhD Ian O’Connell Executive Chairman Chief Executive Officer Chief Financial Officer Liam Tremble Meena Arora Pr
Slide 28: Board Includes Leading Non-Executive Directors
Board Includes Leading Non-Executive Directors A long history of success in the life sciences industry Prof Luke O’Neill Eddie Gibson Prof Brendan Buckley Non-Executive Director Non-Executive Director Non-Executive Director ✓ Co-Founder Inflazome which was acquired ✓ Market access expert ✓ Former Ch
Slide 29: Inhibition of p38 MAPK – A Differentiated Solution For CRS
Inhibition of p38 MAPK – A Differentiated Solution For CRS Mechanism of action • p38 MAPK acts as a gatekeeper to inflammatory responses • Inhibition causes a potent decrease of a wide range of pro-inflammatory cytokines without ablating the immune system • Differentiated mechanism, potential to ame
Slide 30: An Oral p38 MAPK Inhibitor That Selectively Targets Key Inflammatory Pathway
POLB 001 An Oral p38 MAPK Inhibitor That Selectively Targets Key Inflammatory Pathway Without Broad Immunosuppression Phase 2 ready asset with a comprehensive pre-clinical and clinical data package Favourable Safety and Tolerability Profile Designed to Prevent Immunotherapy-Induced CRS 97 subjects d
Slide 31: Potent and Selective Inhibition of p38 MAPK Signalling
POLB 001 Potent and Selective Inhibition of p38 MAPK Signalling Effective target engagement demonstrated in LPS human challenge trial Levels of Phosphorylated p38 MAPK in Circulating Monocytes • POLB 001 was widely distributed • POLB 001 inhibited p38 MAPK activation, direct measurement of activatio
Slide 32: Reduced Key Inflammatory Cytokines Following LPS Challenge
POLB 001 Reduced Key Inflammatory Cytokines Following LPS Challenge Dose dependent reductions, without ablation of immune function TNF-α IL-8 Placebo 30 mg POLB 001 70 mg POLB 001 150 mg POLB 001 TNF-α reduction of 73.5% and 56.2% seen for IL-8 reduction of 80.7% and 76.7% seen for 70 mg and 150 mg
Slide 33: Reduced Key Indicators of LPS-Induced Systemic Inflammation
POLB 001 Reduced Key Indicators of LPS-Induced Systemic Inflammation The reduction of systemic cytokines aligns with improvement in clinically meaningful endpoints Mean Body Temperature Heart Rate Rise (bpm) C-Reactive Protein (CRP) Placebo 30 mg POLB 001 70 mg POLB 001 150 mg POLB 001 No significan
Slide 34: The RISE Programme: Academic & Industry Validation
POLB 001 The RISE Programme: Academic & Industry Validation Poolbeg as lead industry partner in a groundbreaking CRS research programme ABOUT RISE PROGRAMME PARTNERS LED BY R educing University of Manchester – programme lead Dr Jonathan Lim The Christie NHS Trust – clinical lead Clinical Senior Lect
Slide 35: POLB 001: Flu & CRS - Regulatory Exclusivity / Patent Timeline
POLB 001 POLB 001: Flu & CRS - Regulatory Exclusivity / Patent Timeline Market Exclusivity – 11 years Orphan exclusivity* – 10 years Europe & ROW Medical use protection for class of p38 inhibitors – patents granted, further applications pending Market Exclusivity – 5 years Orphan Exclusivity* – 7 ye
Slide 36: Oral Encapsulated GLP-1 - Regulatory Exclusivity / Patent Timeline
Oral Encapsulated GLP-1 Oral Encapsulated GLP-1 - Regulatory Exclusivity / Patent Timeline Exclusively in-licensed rights – patents granted and further applications pending †* Europe Potential for new patent applications to extend term** Exclusively in-licensed rights – patent granted and further ap
Slide 37: Human Challenge Data has Attracted Expert AI Collaborators
Human Challenge Data has Attracted Expert AI Collaborators Novel influenza drug targets successfully identified Successfully identified drugs with potential to combat RSV and prioritised with existing clinical data in other indications CytoReason’s Partners OneThree Biotech’s Partners “Human challen
Slide 38: Stay in touch
Stay in touch Listed on the London Stock Exchange Ticker: POLB Register for RNS alerts 38